Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort

Executive Summary

The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.

You may also be interested in...



AstraZeneca/Sanofi’s RSV Shot Among 13 Hopefuls Awaiting EU Verdict

Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.

Star And Portfolio Firm Electra Roll Out With Focus On Rare Immunologic Disease

Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.

Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel